Sanofi (SNY) has released an update.
Sanofi has announced the European Medicines Agency’s approval of Dupixent, the first targeted therapy for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in the EU. The approval is a significant advancement as Dupixent is the first new treatment option for COPD in over a decade, offering improved lung function and quality of life for approximately 220,000 adults in the EU. This marks the sixth EU and seventh global indication approval for Dupixent, with further submissions under review worldwide.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
